144 related articles for article (PubMed ID: 16700912)
1. Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629].
Silva SY; Rueda LC; López M; Vélez ID; Rueda-Clausen CF; Smith DJ; Muñoz G; Mosquera H; Silva FA; Buitrago A; Díaz H; López-Jaramillo P
Trials; 2006 May; 7():14. PubMed ID: 16700912
[TBL] [Abstract][Full Text] [Related]
2. Double blind, randomized, placebo controlled clinical trial for the treatment of diabetic foot ulcers, using a nitric oxide releasing patch: PATHON.
Silva SY; Rueda LC; Márquez GA; López M; Smith DJ; Calderón CA; Castillo JC; Matute J; Rueda-Clausen CF; Orduz A; Silva FA; Kampeerapappun P; Bhide M; López-Jaramillo P
Trials; 2007 Sep; 8():26. PubMed ID: 17897470
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
Firooz A; Khamesipour A; Ghoorchi MH; Nassiri-Kashani M; Eskandari SE; Khatami A; Hooshmand B; Gorouhi F; Rashighi-Firoozabadi M; Dowlati Y
Arch Dermatol; 2006 Dec; 142(12):1575-9. PubMed ID: 17178983
[TBL] [Abstract][Full Text] [Related]
4. A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis.
López-Jaramillo P; Rincón MY; García RG; Silva SY; Smith E; Kampeerapappun P; García C; Smith DJ; López M; Vélez ID
Am J Trop Med Hyg; 2010 Jul; 83(1):97-101. PubMed ID: 20595484
[TBL] [Abstract][Full Text] [Related]
5. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
[TBL] [Abstract][Full Text] [Related]
7. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
8. Allopurinol in the treatment of American cutaneous leishmaniasis.
Martinez S; Marr JJ
N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Munir A; Janjua SA; Hussain I
Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
[TBL] [Abstract][Full Text] [Related]
11. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
Shanehsaz SM; Ishkhanian S
Int J Dermatol; 2015 Jul; 54(7):834-8. PubMed ID: 26108265
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
Momeni AZ; Aminjavaheri M
Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis.
Iraji F; Vali A; Asilian A; Shahtalebi MA; Momeni AZ
Dermatology; 2004; 209(1):46-9. PubMed ID: 15237267
[TBL] [Abstract][Full Text] [Related]
14. Comparison of oral itraconazole and intramuscular meglumine antimoniate in the treatment of cutaneous leishmaniasis.
Saleem K; Rahman A
J Coll Physicians Surg Pak; 2007 Dec; 17(12):713-6. PubMed ID: 18182133
[TBL] [Abstract][Full Text] [Related]
15. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Intralesional Meglumine Antimonite along with oral Itraconazole to Intralesional Meglumine Antimonite in the treatment of Cutaneous Leishmaniasis.
Bashir U; Tahir M; Anwar MI; Manzoor F
Pak J Med Sci; 2019; 35(6):1669-1673. PubMed ID: 31777513
[TBL] [Abstract][Full Text] [Related]
18. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.
Nascimento E; Fernandes DF; Vieira EP; Campos-Neto A; Ashman JA; Alves FP; Coler RN; Bogatzki LY; Kahn SJ; Beckmann AM; Pine SO; Cowgill KD; Reed SG; Piazza FM
Vaccine; 2010 Sep; 28(40):6581-7. PubMed ID: 20688040
[TBL] [Abstract][Full Text] [Related]
20. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
Sadeghian G; Nilforoushzadeh MA
Int J Dermatol; 2006 Jul; 45(7):819-21. PubMed ID: 16863518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
